Free for academic non-profit institutions. Other users need a Commercial license
This gene produces a long non-coding RNA that regulates the reprogramming of pluripotent stem cells. This RNA suppresses induction of tumor protein p53 after DNA damage. It is thought to act as a sponge for microRNAs that regulate stem cell factors POU class 5 homeobox 1, Nanog, and SRY-box 2. This RNA may also have a extracellular role in modulating response to hypoxia in hepatocellular cancer cells. Expression of this transcript is associated with tumor progression and epithelial to mesenchymal transition and metastasis. [provided by RefSeq, Dec 2017]
LINC-ROR (Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming) is an RNA Gene, and is affiliated with the lncRNA class. Diseases associated with LINC-ROR include Triple-Receptor Negative Breast Cancer and Gallbladder Cancer. Among its related pathways are LncRNA-mediated mechanisms of therapeutic resistance.
GeneHancer (GH) Identifier | GH Type | GH Score |
GH Sources | Gene Association Score | Total Score | TSS distance (kb) | Number of Genes Away | Size (kb) | Transcription Factor Binding Sites |
Gene Targets |
---|---|---|---|---|---|---|---|---|---|---|
GH18J057069 | Promoter | 0.8 | EPDnew Ensembl | 250.7 | +1.7 | 1713 | 3.6 | ZBTB10 | AB844430 HSALNG0121747 LINC-ROR piR-37656-105 piR-32559-195 HSALNG0121745 LC027889 BOD1L2 TXNL1 | |
GH18J057062 | Enhancer | 0.3 | Ensembl | 0.4 | +8.3 | 8291 | 2.4 | PRDM4 EP300 | piR-32559-194 AB844430 LC027889 LINC-ROR HSALNG0121745 BOD1L2 TXNL1 | |
GH18J057075 | Enhancer | 0.2 | ENCODE | 0.7 | -3.6 | -3611 | 0.2 | HSALNG0121748 LINC-ROR HSALNG0121747 HSALNG0121745 BOD1L2 TXNL1 | ||
GH18J057076 | Enhancer | 0.2 | ENCODE | 0.7 | -3.9 | -3875 | 0.1 | HSALNG0121748 LINC-ROR HSALNG0121747 HSALNG0121745 BOD1L2 TXNL1 |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | LncRNA-mediated mechanisms of therapeutic resistance |
RNAcentral Transcript ID | Subcategory | Length (nts) | # of Sources | Source Identifiers and Annotations |
---|---|---|---|---|
URS000083C204_9606 | lncRNA | 2191 | 3 |
Ensembl: ENST00000645956 (view in UCSC) , LNCipedia: LINC-ROR:9, ENA: LC027886.1:1..2186:ncRNA, |
URS00008145B3_9606 | lncRNA | 769 | 3 |
Ensembl: ENST00000643706 (view in UCSC) , LNCipedia: LINC-ROR:7, ENA: AB908956.1:1..766:ncRNA, |
URS000081DD87_9606 | lncRNA | 568 | 3 |
Ensembl: ENST00000644575 (view in UCSC) , LNCipedia: LINC-ROR:10, ENA: AB932951.1:1..568:ncRNA, |
URS0000D62423_9606 | lncRNA | 2608 | 2 |
Ensembl: ENST00000553704 (view in UCSC) , LNCipedia: LINC-ROR:6, |
URS00007681C7_9606 | lncRNA | 2603 | 2 |
RefSeq: NR_048536, LNCipedia: LINC-ROR:4, |
Variant ID | Type | Subtype | PubMed ID |
---|---|---|---|
dgv5954n54 | CNV | loss | 21841781 |
esv2437519 | CNV | insertion | 19546169 |
esv3431467 | CNV | duplication | 20981092 |
esv3448993 | CNV | duplication | 20981092 |
nsv1056480 | CNV | gain | 25217958 |
nsv458083 | CNV | loss | 19166990 |
Disorder | Aliases | PubMed IDs |
---|---|---|
triple-receptor negative breast cancer |
|
|
gallbladder cancer |
|
|
nasopharyngeal carcinoma |
|
|
endometrial cancer |
|
|
lung cancer susceptibility 3 |
|